The effects of age and lipopolysaccharide (LPS)-mediated peripheral inflammation on numbers of central catecholaminergic neurons

Neurobiology of Aging

Volumn 33, Issue 2, 2012, Pages 423.e27-423.e36

  Mouton, P R ^a,b,c   Kelley Bell, B ^a   Tweedie, D ^d   Spangler, E L ^a   Perez, E ^a   Carlson, O D ^a   Short, R G ^a   deCabo, R ^a   Chang, J ^a   Ingram, D K ^e   Li, Y ^a   Greig, N H ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c Stereology Resource Center   (United States)

^d MEDSTAR HEALTH RESEARCH INSTITUTE   (United States)

^e LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

Age related neuron loss; Computerized stereology; Neuroinflammation; Parkinsonism; Stereologer; Substantia nigra; Ventral tegmental area

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; TYROSINE 3 MONOOXYGENASE;

AGE; ANIMAL TISSUE; ARTICLE; CATECHOLAMINE NERVE CELL; CATECHOLAMINERGIC SYSTEM; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFLAMMATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEREOLOGY; SUBSTANTIA NIGRA PARS COMPACTA; VENTRAL TEGMENTUM;

EID: 82755195000     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2010.09.025     Document Type: Article

References (69)

1. Aarsland D., Andersen K., Larsen J.P., Lolk A., Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch. Neurol 2003, 60:387-392.
2. Arai H., Furuya T., Yasuda T., Miura M., Mizuno Y., Mochizuki H. Neurotoxic effects of lipopolysaccharide on nigral dopaminergic neurons are mediated by microglial activation, interleukin-1beta, and expression of caspase-11 in mice. J. Neurochem 2004, 2003(5):1201-1212.
3. Banks W.A., Robinson S.M. Minimal penetration of lipopolysaccharide across the murine blood-brain barrier. Brain Behav. Imm 2010, 24:102-109.
4. Bedard P.J., Di Paolo T., Falardeau P., Boucher R. Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding. Brain Res 1986, 379:294-299.
5. Berger K., Przedborski S., Cadet J.L. Retrograde degeneration of nigrostriatal neurons induced by intrastriatal 6-hydroxydopamine injection in rats. Brain Res. Bull 1991, 26:301-307.
6. Betarbet R., Sherer T.B., Greenamyre J.T. Animal models of Parkinson's disease. Bioessays 2002, 24:308-318.
7. Burns R.S., Markey S.P., Phillips J.M., Chiueh C.C. The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the monkey and man. Can. J. Neurol. Sci 1984, 11:166-168.
8. Cabello C.R., Thune J.J., Pakkenberg H., Pakkenberg B. Ageing of substantia nigra in humans: cell loss may be compensated by hypertrophy. Neuropathol. Appl. Neurobiol 2002, 28:283-291.
9. Cadet J.L., Last R., Kostic V., Przedborski S., Jackson-Lewis V. Long-term behavioral and biochemical effects of 6-hydroxydopamine injections in rat caudate-putamen. Brain Res. Bull 1991, 26:707-713.
10. Chan P., Di Monte D.A., Langston J.W., Janson A.M. (+) MK-801 does not prevent MPTP-induced loss of nigral neurons in mice. J. Pharmacol. Exp. Ther 1997, 280:439-446.
11. Chan-Palay V., Asan E. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. J. Comp. Neurol 1989, 287:373-392.
12. Coggeshall R.E., Lekan H.A. Methods for determining numbers of cells and synapses: a case for more uniform standards of review. J. Com. Neurol 1996, 364:6-15.
13. Date I., Felten S.Y., Felten D.L. Cografts of adrenal medulla with peripheral nerve enhance the survivability of transplanted adrenal chromaffin cells and recovery of the host nigrostriatal dopaminergic system in MPTP-treated young adult mice. Brain Res. 1990, 537:33-39.
14. Datta S.C., Opp M.R. Lipopolysaccharide-induced increases in cytokines in discrete mouse brain regions are detectable using Luminex xMAP technology. J. Neurosci. Methods 2008, 175:119-124.
15. Dentener M.A., Von Asmuth E.J., Francot G.J., Marra M.N., Buurman W.A. Antagonistic effects of lipopolysaccharide binding protein and bactericidal/permeability-increasing protein on lipopolysaccharide-induced cytokine release by mononuclear phagocytes. Competition for binding to lipopolysaccharide. J. Immunol 1993, 151:4258-4265.
16. Dutta G., Zhang P., Liu B. The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery. Fundam. Clin. Pharmacol 2008, 22:453-464.
17. Evans S.M., Janson A.M., Nyengaard J.R. Quantitative Methods in Neuroscience: a Neuroanatomical Approach 2004, Oxford University Press, New York.
18. Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann. N.Y. Acad. Sci 2003, 991:1-14.
19. Gayle D.A., Ling Z., Tong C., Landers T., Lipton J.W., Carvey P.M. Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-alpha, interleukin-1beta, and nitric oxide. Brain Res. Dev. Brain Res 2002, 133:27-35.
20. German D.C., Manaye K.F., White C.L., Woodward D.J., McIntire D.D., Smith W.K., Kalaria R.N., Mann D.M. Disease-specific patterns of locus coeruleus cell loss. Ann. Neurol. 1992, 32:667-676.
21. Gioannini T.L., Weiss J.P. Regulation of interactions of Gram-negative bacterial endotoxins with mammalian cells. Immunol. Res 2007, 39:249-260.
22. Gundersen H.J.G., Jensen E.B.V., Kieu K., Nielsen J. The efficiency of systematic sampling in stereology - reconsidered. J. Microsc 1999, 193:199-211.
23. Herrera A.J., Castano A., Venero J.L., Cano J., Machado A. The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol. Dis 2000, 7:429-447.
24. Howard C.V., Reed M.G. Unbiased Stereology: Three Dimensional Measurement in Microscopy 2005, Taylor & Francis, London.
25. Hunot S., Dugas N., Faucheux B., Hartmann A., Tardieu M., Debre P., Agid Y., Dugas B., Hirsch E.C. FcepsilonRII/CD23 is expressed in Parkinson's disease and induces in vitro production of nitric oxide and tumor necrosis factor-alpha in glial cells. J. Neurosci 1999, 19:3440-3447.
26. Iravani M.M., Kashefi K., Mander P., Rose S., Jenner P. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. J. Neurosci 2002, 110:49-58.
27. Irwin I., DeLanney L.E., Langston J.W. MPTP and aging. Stud. in The C, 57BL/6 mouse. Adv. Neurol 1993, 60:197-206.
28. Kim W.G., Mohney R.P., Wilson B., Jeohn G.H., Liu B., Hong J.S. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J. Neurosci 2000, 20:6309-6316.
29. Koprich J.B., Reske-Nielsen C., Mithal P., Isacson O. Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. J. Neuroinflammation 2008, 5:8.
30. Langston J.W., Ballard P.A. Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N Engl J. Med 1983, 309:310-315.
31. Long J.M., Kalehua A.N., Muth N.J., Hengemihle J.M., Jucker M., Calhoun M.E., Ingram D.K., Mouton P.R. Stereological estimation of total microglia number in mouse hippocampus. J. Neurosci. Methods 1998, 84:101-108.
32. Lu X., Bing G., Hagg T. Naloxone prevents microglia-induced degeneration of dopaminergic substantia nigra neurons in adult rats. J. Neurosci 2000, 97:285-291.
33. Ma S.Y., Rottta M., Rinne J.O., Collan Y., Rinne U.K. Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson's disease using disector counts. J. Neurol. Sci 1997, 151:83-87.
34. McCormack A.L., Di Monte D.A., Delfani K., Irwin I., DeLanney L.E., Langston W.J., Janson A.M. Aging of the nigrostriatal system in the squirrel monkey. J. Comp. Neurol 2004, 471:387-395.
35. McNeill T.H., Koek L.L. Differential effects of advancing age on neurotransmitter cell loss in the substantia nigra and striatum of C57BL/6N mice. Brain Res. 1990, 521:107-117.
36. Medvedev A.E., Kopydlowski K.M., Vogel S.N. Inhibition of lipopolysaccharide-induced signal transduction in endotoxin-tolerized mouse macrophages: dysregulation of cytokine, chemokine, and toll-like receptor 2 and 4 gene expression. J. Immunol 2000, 164:5564-5574.
37. Miyake K. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin. Immunol 2007, 19:3-10.
38. Mogi M., Harada M., Kondo T., Riederer P., Inagaki H., Minami M., Nagatsu T. Interleukin-1beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci. Lett 1994, 180:147-150.
39. Mogi M., Harada M., Narabayashi H., Inagaki H., Minami M., Nagatsu T. Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile Parkinsonism and Parkinson's disease. Neurosci. Lett 1996, 21:13-16.
40. Møller A. Mean volume of pigmented neurons in the substantia nigra in Parkinson's disease. Acta Neurol. Scand. Suppl. 1992, 137:37-39.
41. Mouton P.R., Pakkenberg B., Gundersen H.J.G., Price D.l. Absolute number and size of pigmented locus coeruleus neurons in the brains of young and aged individuals. J. Chem. Neuroanat 1994, 7:185-190.
42. Mouton P.R. Principles and Practices of Unbiased Stereology: an Introduction for Bioscientists 2002, The Johns Hopkins University Press, Baltimore.
43. Mouton P.R., Long J.M., Lei D.L., Howard V., Jucker M., Calhoun M.E., Ingram D.K. Age and gender effects on microglia and astrocyte numbers in brains of mice. Brain Res 2002, 956:30-35.
44. Mouton P.R., Gordon M. Stereological and image analysis techniques for quantitative assessment of neurotoxicology. Neurotoxicology 2010, Taylor and Francis, Philadelphia, Target Organ Toxicology Series. 3rd Edition. Harry, Tilson (Eds.).
45. Mouton P.R. Applications of unbiased stereology to neurodevelopmental toxicology. Developmental Neurotoxicology Research: Principles, Models, Techniques, Strategies and Mechanisms 2009, John Wiley & Sons, Hoboken. C. Wang, W. Slikker (Eds.).
46. Ohm T.G., Busch C., Bohl J. Unbiased estimation of neuronal numbers in the human nucleus coeruleus during aging. Neurobiol. Aging 1997, 18:393-399.
47. O'Neil J.N., Mouton P.R., Tizabi Y., Ottinger M.A., Lei D.L., Ingram D.K., Manaye K.F. Catecholaminergic neuronal loss in locus coeruleus of aged female dtg APP/PS1 mice. J. Chem. Neuroanat 2007, 34:102-107.
48. Orth M., Tabrizi S.J. Models of Parkinson's disease. Mov. Disord 2003, 2018:729-737.
49. Pakkenberg B., Mœller A., Gundersen H.J.G., Dam A.M., Pakkenberg H. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J. Neurol. Neurosurg. Psychiatry 1991, 54:30-33.
50. Qin L., Wu X., Block M.L., Liu Y., Breese G.R., Hong J.S., Knapp D.J., Crews F.T. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007, 55:453-462.
51. Ricaurte G.A., Irwin I., Forno L.S., DeLanney L.E., Langston E., Langston J.W. Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra. Brain Res. 1987, 403:43-51.
52. Rudow G., O'Brien R., Savonenko A.V., Resnick S.M., Zonderman A.B., Pletnikova O., Marsh L., Dawson T.M., Crain B.J., West M.J., Troncoso J.C. Morphometry of the human substantia nigra in ageing and Parkinson's disease. Acta Neuropathol. 2008, 115:461-470.
53. Sanlioglu S., Williams C.M., Samavati L., Butler N.S., Wang G., McCray P.B., Ritchie T.C., Hunninghake G.W., Zandi E., Engelhardt J.F. Lipopolysaccharide induces Rac1-dependent reactive oxygen species formation and coordinates tumor necrosis factor-alpha secretion through IKK regulation of NF-kappaB. J. Biol. Chem 2001, 276:30188-30198.
54. Saitoh T., Niijima K., Mizuno Y. Long-term effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal dopamine content in young and mature mice. J. Neurol. Sci 1987, 77:229-235.
55. Saper C.B. Any way you cut it: a new journal policy for the use of unbiased counting methods. J. Comp. Neurol 1996, 364:5.
56. Sauer H., Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. J. Neurosci 1994, 59:401-415.
57. Schumann R.R., Leong S.R., Flaggs G.W., Gray P.W., Wright S.D., Mathison J.C., Tobias P.S., Ulevitch R.J. Structure and function of lipopolysaccharide binding protein. Science 1990, 249:1429-1431.
58. Scott S.A., Diaz N.M., Ahmad S.O. Stereologic analysis of cell number and size during postnatal development in the rat substantia nigra. Neurosci. Lett 2007, 419:34-37.
59. Shibata H., Katsuki H., Nishiwaki M., Kume T., Kaneko S., Akaike A. Lipopolysaccharide-induced dopaminergic cell death in rat midbrain slice cultures: role of inducible nitric oxide synthase and protection by indomethacin. J. Neurochem 2003, 86:1201-1212.
60. Siddiqi Z., Kemper T.L., Killiany R. Age-related neuronal loss from the substantia nigra-pars compacta and ventral tegmental area of the rhesus monkey. J. Neuropathol. Exp. Neurol 1999, 58:959-971.
61. Singh A.K., Jiang Y. How does peripheral lipopolysaccharide induce gene expression in the brain of rats?. Toxicology 2004, 201:197-207.
62. Spandidos A., Wang X., Wang H., Dragnev S., Thurber T., Seed B. A comprehensive collection of experimentally validated primers for Polymerase Chain Reaction quantitation of murine transcript abundance. BMC Genomics 2008, 9:633-641.
63. Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci. 2007, 30:244-250.
64. Tatton W.G., Greenwood C.E., Verrier M.C., Holland D.P., Kwan M.M., Biddle F.E. Different rates of age-related loss for four murine monoaminergic neuronal populations. Neurobiol. Aging 1991, 12:543-556.
65. Thiruchelvam M., McCormack A., Richfield E.K., Baggs R.B., Tank A.W., Di Monte D.A., Cory-Slechta D.A. Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype. Eur. J. Neurosci 2003, 18:589-600.
66. Wang X., Seed B. A PCR primer bank for quantitative gene expression analysis. Nucleic Acids Res. 2003, 31:1-8.
67. West M.J., Slomianka L., Gundersen H.J. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat. Rec 1991, 231:482-497.
68. Wilms H., Zecca L., Rosenstiel P., Sievers J., Deuschl G., Lucius R. Inflammation in Parkinson's diseases and other neurodegenerative diseases: cause and therapeutic implications. Curr. Pharm. Des 2007, 13:1925-1928.
69. Zhang J., Stanton D.M., Nguyen X.V., Liu M., Zhang Z., Gash D., Bing G. Intrapallidal lipopolysaccharide injection increases iron and ferritin levels in glia of the rat substantia nigra and induces locomotor deficits. Neuroscience 2005, 135:829-838.